title: Contrast-enhanced MR imaging of the liver: comparison between Gd-BOPTA and Mangafodipir.
abstract: The purpose of the study was to evaluate the MR contrast agents gadolinium benzyloxypropionictetro-acetate (Gd-BOPTA) and Mangafodipir for liver enhancement and the lesion-liver contrast on T1W spin-echo (SE) and gradient-recalled-echo (GRE) images. Fifty-one patients (three groups of 17 patients each) with known or suspected liver lesions were evaluated with T1W SE (300/12) and GRE (77-80/2.3-2.5/80 degrees) images before and after intravenous (IV) Gd-BOPTA (0.1 or 0.05 mmol/kg) or Mangafodipir (5 mumol/kg) in phase II to III clinical trials. Quantitative analysis by calculating liver signal-to-noise ratio (SNR), lesion-liver contrast-to-noise ratio (CNR), and spleen-liver CNR was performed. Liver SNR and spleen-liver CNR were always significantly increased postcontrast. SNR was highest after application of 0.1 mmol/kg Gd-BOPTA (51.3 +/- 3.6, P < .05). CNR was highest after Mangafodipir (-22.6 +/- 2.7), but this was not significantly different from others (P = .07). Overall, GRE images were superior to SE images for SNR and CNR. Mangafodipir and Gd-BOPTA (0.1 mmol/kg) provide equal liver enhancement and lesion conspicuity postcontrast. By all criteria, contrast-enhanced T1-weighted GRE were comparable to SE images.
authors.affiliation: Department of Radiology, Massachusetts General Hospital, Boston, USA.
authors.forename: W
authors.initials: W
authors.lastname: Schima
authors.forename: J
authors.initials: J
authors.lastname: Petersein
authors.forename: P F
authors.initials: PF
authors.lastname: Hahn
authors.forename: M
authors.initials: M
authors.lastname: Harisinghani
authors.forename: E
authors.initials: E
authors.lastname: Halpern
authors.forename: S
authors.initials: S
authors.lastname: Saini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D002614:Chelating Agents / Q000008:administration & dosage; D003287:Contrast Media; D004492:Edetic Acid / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007262:Infusions, Intravenous; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000175:diagnosis*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage; D012680:Sensitivity and Specificity
chemical_list: D002614:Chelating Agents; D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D004492:Edetic Acid